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Introduction
Analysis of various symptoms from 20000 FMF patients
indicates that several issues, including the clinical manifes-
tation in a variety of combinations and the genotype pene-
trance, make FMF diagnosis and management challenging.
Severe phenotypes with development of serositis, ELE,
splenomegaly, and vasculitis are associated with high
penetrance mutations of exon 10, mainly M694V allele.
Objectives
Several forms of arthritis were associated with FMF and
the life-threatening complications such as adhesive intest-
inal obstruction were present in some patients as the first
and only manifestation of FMF. Family studies revealed
the personalized nature of FMF symptoms and treatment
based on genotype and other environmental factors. A sig-
nificant number of patients have to endure pain for a long
time before being properly diagnosed or treated. A major
cause for such complexity could be the presence of less
common FMF symptoms such as fibromyalgia or multiple
sclerosis.
Methods
Phenotype-genotype correlation was performed after
molecular-genetic testing of FMF patients and their
family members.
Results
FMF patient management may seem straightforward due
to general response to colchicine therapy yet many issues
including but not limited to misdiagnosis, delayed diagno-
sis, and renal amyloidosis could potentially complicate the
patient management. We have observed a limited response
to colchicine at the nephrotic stage of renal amyloidosis in
FMF patients homozygous for M694V mutation. Almost
all such patients have SAA1 a/a genotype suggesting that
homozygous M694V patients could benefit from SAA1
genotyping for colchicine dosage adjustment and manage-
ment of renal amyloidosis. FMF patients with other geno-
types had a good chance to ameliorate the nephrotic
syndrome and to maintain renal function. Presence of
only one symptom in FMF has been a major factor for
misdiagnosis and delay in treatment further emphasizing
that mutations in MEFV gene could result in various
forms and combinations of symptoms in different indivi-
duals. Diagnosis of member of family with FMF while his
father and sister had the same genotype and no symptoms
also points to a personalized development and progression
of the disease. Therefore each case should be discussed in
details using genotype and symptoms correlation and trea-
ted accordingly.
Conclusion
In our experience prevention of the attacks has been a
useful tool in patient management. Abrupt and extreme
changes in weather patterns, strenuous activity or exercise,
anxiety and stress, and even diet have triggered FMF
attacks. These conditions either cause additional inflam-
mation or lower/distort the effectiveness of Pyrin in
patients with affected genotypes. Although colchicine
therapy remains the dominant treatment for FMF and
largely prevents the development of renal amyloidosis, its
effect in some cases remains controversial. Of course for
genotypes with potential for amyloidosis analysis of SAA1
gene could provide preventive values. Once the diagnosis
is final immediate initiation of colchicine therapy could
prevent renal complications yet emphasis on identifying
environmental and/or social factors that trigger FMF
attacks could reduce their frequency and facilitate patient
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